This inventor holds 3 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2009-2025.
Company Filing History:
Years Active: 2009-2025
Title: The Innovative Contributions of Peter End
Introduction
Peter End is a notable inventor based in Oberwil, Switzerland. He has made significant contributions to the field of medicine, particularly in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). With a total of 3 patents to his name, End's work has the potential to impact many lives.
Latest Patents
Among his latest patents, End has developed methods of using factor B inhibitors. These methods describe the treatment of PNH with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, such as LNP023 hydrochloride. This innovative approach showcases his commitment to advancing medical treatments.
Career Highlights
Throughout his career, Peter End has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Novartis Pharma GmbH. His experience in these organizations has undoubtedly contributed to his expertise and success as an inventor.
Collaborations
End has collaborated with talented individuals in his field, including Irina Baltcheva and Julie Marie-Pomme Gabrielle Milojevic. These partnerships have likely enriched his work and fostered innovation.
Conclusion
Peter End's contributions to the field of medicine through his patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in treatment options for patients suffering from PNH.